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Anti-HBs levels in infants of hepatitis B 
carrier mothers after delayed active 
immunization with recombinant vaccine 
concomitant with DTP-polio vaccine: is 
there need for a second dose of HBIg? 
P.M. Grosheide*, R. del Canho*, M. Voogd*, R.A. Heijtink t, S.W. Schalm *~ 
and the Dutch Study Group on Prevention of Neonatal Hepatitis B $ 
The need.for an additional dose of hepatitis B immune globulin (HBIg) was studied by 
comparing infants receiving 1 ml HBI9 at birth Jollowed by hepatitis B immunization, 
concomitant with DTP-polio vaccine, at 3, 4, 5 and 11 months (schedule E), with infants 
receiving the same schedule with additional HBI9 at 3 months (schedule F). The immune 
response to recombinant hepatitis B vaccine (20 #g) was evaluated in 195 infants born to 
HBsAg-positive mothers allocated to groups E and F and compared with historic controls 
who received plasma vaccine (10 Pg) according to schedule F. Blood samples were drawn 
at O, 3, 4, 6, 11, 12 and 24 months of age. No difference in efficao' between the two 
schedules was observed," 8 and 6% of infants born to HBeAg-positive HBsA 9 carrier 
mothers in groups E and F, respectively, became HBsA 9 carriers. Passively acquired 
antibodies at birth remained present for about 5 months in most infants. The seroprotection 
rates (anti-HBs ~ 10 IU l-1) were over 90% at all time points and similar for groups E 
and F. The titres of anti-HBs attained uring the first 6 months were statistically lower 
(p ~< 0.02) for group E than for group F but similar thereafter. Anti-HBs titres in infants 
receiving the recombinant vaccine were significantly lower than in infants receiving the 
plasma vaccine (p<<O.O01). Supplemental doses of HBI9 in infants receiving a high dose 
of HBI9 ( > 200 IU) at birth and the first dose of vaccine at the age of 3 months are not 
advised. 
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In a large Dutch study a schedule of passive 
immunization starting within 2h of birth and active 
immunization with plasma-derived vaccine at 3, 4, 5 and 
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11 months prevented significant hepatitis B virus 
infection in infants of hepatitis B surface antigen (HBsAg) 
carrier mothers 1-3. The delayed active hepatitis B 
immunization, starting at 3 months of age concomitant 
with DTP-polio vaccine, had a similar protective fficacy 
as the generally recommended schedule of immunization 
starting immediately after birth (0, 1, 2, ! 1 months) but 
gave rise to higher anti-HBs titres z'3. Infants on the 
delayed immunization schedule received a second dose 
of anti-HBs immune globulin (HBIg) at 3 months of age, 
and at the same time active immunization with the 
plasma-derived vaccine was started. 
For practical and economic reasons, the simultaneous 
administration of DTP-polio vaccine and hepatitis B 
vaccine has been accepted in the Netherlands as the 
regimen of choice for the prevention of perinatal hepatitis 
B. However, in view of the levels of anti-HBs observed at 
3 months of age, the need for the second dose of HBIg 
is uncertain 2--4. Practical and economic reasons trongly 
favour the elimination of the HBIg injection at 3 months 
of age. The present study examines the anti-HBs levels 
in infants, born to HBsAg-positive mothers, receiving a 
high dose of HBIg at birth and recombinant hepatitis B 
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vaccine at 3, 4, 5 and 11 months, either with or without 
a second dose of HBIg at 3 months of age. 
To confirm evidence that the immune response to the 
yeast-derived recombinant hepatitis B vaccine is similar 
to the response to the plasma-derived vaccine, we also 
compared the anti-HBs levels of infants receiving 
recombinant vaccine with the results found previously in 
infants using the same immunization regimens with the 
Merck plasma vaccine 2's 
PAT IENTS AND METHODS 
Procedure 
The study population consisted of healthy infants born 
to HBsAg-positive carrier mothers in three large city 
hospitals in Utrecht and Rotterdam and in one rural area 
providing prenatal and obstetric services. Entry to the 
study, which was approved by the medical ethics 
committees at each of the four participating centres, 
started on 1 January 1988 and ended on 1 October 1989. 
All pregnant women who attended the prenatal clinic at 
one of the participating centres were screened for the 
presence of HBsAg during their first visit. Pregnant 
women with a positive test result from the initial visit 
underwent a repeated test for HBsAg at delivery to verify 
the eligibility of infants for the study. Pregnant women 
who were positive for HBsAg were also tested for the 
presence of HBeAg. At the prenatal visit following the 
diagnosis of HBsAg positivity, the mother was informed 
about the immunization study programme. Informed 
consent was obtained from the mother for the 
participation of her infant. Each infant received l ml 
injection of HBIg intramuscularly within 2 h of birth. 
After referral to the paediatrician, infants in Rotterdam, 
were given 1 ml of recombinant vaccine at 3, 4, 5 and 11 
months of age (group E). Infants born in Utrecht and 
the rural area were assigned to group F and were given 
the same schedule as infants in group E, but received an 
additional dose of 1 ml HBIg at 3 months of age. The 
parent or guardian was asked to record any local or 
systemic reaction for 5 days after each vaccine injection. 
Immediately after delivery cord blood was obtained 
after cleansing of the umbilical cord. Follow-up blood 
samples were taken at 3, 4, 6 and 1! months and at the 
ages of 1 and 2 years (Figure 1). 
Infants of HBsAg-positive mothers on the same 
schedule of passive-active immunization as the infants 
in group F, but who received 10 #g of the plasma-derived 
vaccine (HBvax; Merck, Sharp & Dohme, 20#g ml-1) 
served as historic controls. Results of the study on the 
protective fficacy and immunogenicity of the plasma- 
derived hepatitis B vaccine in infants of HBsAg-positive 
mothers have been reported previously 1 3. 
group E I V V v V 
group F I I+V V V V 
/ /  
0 3 4 5 6 i i  12 24 months  
Figure 1 Passive--active immunization schedule: I, HBIg administered 
(200 IU anti-HBs ml-1); V, vaccine administered (20ug Engerix-B ml-1); 
,L, blood sample taken (historic controls received 10/~g plasma vaccine 
(HBvax) according to schedule F) 
Laboratory tests 
All serum samples obtained from mothers during the 
course of the study were tested for HBsAg and HBeAg 
by radioimmunoassay (Abbott Laboratories, Chicago, 
IL, USA). Serum samples from infants were assayed for 
anti-HBs by radioimmunoassay (Abbott). The results 
were expressed in international units per litre (IU 1-1). 
Blood samples obtained at 12 and 24 months of age were 
also assayed for anti-HBc, and for HBsAg in cases where 
anti-HBs titres had dropped below 100 IU l -1  
Hepatitis B immune globulin 
Hepatitis B immune globulin was prepared by the 
Central Laboratory of the Netherlands Red Cross Blood 
Transfusion Service, Amsterdam. The HBIg was supplied 
in vials of l ml and stored at 2-8°C. The full dose of 
HBIg, I ml containing 200 to 250 IU anti-HBs, was given 
intramuscularly in the anterolateral region of the thigh. 
Vaccine 
The recombinant hepatitis B vaccine, alum adsorbed, 
prepared by SmithKline Biologicals, Rixensart, Belgium, 
was used. The vaccine was stored at 2-8°C. The vaccine 
dose of 1 ml (20 #g) was given intramuscularly in the 
anterolateral part of the other thigh in cases of 
concomitant injection of HBIg. 
Statistics 
The degree of simlarity between the two treatment 
groups was demonstrated by comparing baseline 
characteristics (e.g. parity, age) of the HBsAg-positive 
mothers. Differences in proportions were compared using 
the Z 2 test and Fisher's exact est. Median ages of mothers 
were compared using the Wilcoxon test. Differences in 
anti-HBs seroconversion rates between treatment groups 
were calculated using the Fisher's exact test and 95% 
confidence intervals (95% CI). The exact values for 95% 
CI are given in Geigy Scientific Tables 6. The geometric 
mean titres (GMTs) were calculated only for those infants 
who had anti-HBs >/10 IU 1-1. Anti-HBs levels were 
compared using the Wilcoxon rank sum test. The 
Wilcoxon Mann-Whitney test was used to compare the 
median immunization intervals between groups. 
RESULTS 
Participants 
During the study period 210 infants were born to the 
mothers who had agreed to participate in the study. Nine 
infants were withdrawn from the trial by their parents 
before the treatment had started. Thus 201 infants entered 
the study, of whom six infants, three in each group, were 
excluded from the final analysis because they received an 
incorrect vaccination schedule. In all six infants the last 
available blood sample tested was negative for HBsAg. 
Results for the 195 infants who were studied for at 
least 6 months are presented; 102 were on schedule E 
and 93 on schedule F. In Table 1 comparisons between 
treatment groups are presented. 
In both groups 97% of infants received HBIg at birth 
and all injections: 99 infants in group E and 90 infants 
in group F. Blood samples at 12 and 24 months of age 
were taken from 88 and 86% of infants in group E and 
74 and 73% of infants in group F, respectively. 
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Anti-HBs response 
The distribution of the anti-HBs titres of infants during 
the 2 years of follow-up is shown in Table2. The 
seroconversion rates (anti-HBs >~ 10 IU 1-1) were similar 
for both groups at all months studied: more than 92% 
at all times and above 97% from month 6 onwards. The 
geometric mean antibody titres of vaccinees with 
anti-HBs ~> 10IUI-1 were significantly higher for 
treatment group F at months 3, 4 and 6. These differences 
were no longer significant at 11, 12 and 24 months of age. 
Recombinant vaccine compared with plasma vaccine 
A comparison of infants on schedule F and the historic 
controls receiving the same vaccination regimen with the 
plasma vaccine is presented in Table 3. The percentage 
of infants seroconverting for anti-HBs was similar for 
Table 1 Comparison of the characteristics between study groups 
Schedule E Schedule F 
Mothers (n = 102) (n =93) p value 
Median age (years) 26 (18-38) a 27 (18-40) 
HBeAg-positive, no. (%) 13 (13) 17 (18) 
Primigravidae, no. (%) 36 (35) 26 (28) 
Country of birth, no. (%) 
Netherlands+other 27 (26) 12 (13). 
Mediterranean 48 (47) 64 (69) 
Surinam 14 (14) 3 (3) 
Asia 13 (13) 14 (15) 
0.86 b 
0.28 ° 
0.27 ° 
0.002 c 
aNumbers in parentheses indicate 5th to 95th 
t'Wilcoxon test 
c•2 test 
percentiles 
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both vaccines. Significantly higher GMTs were obtained 
with the plasma vaccine than with the recombinant 
vaccine, both after the initial series of vaccination at 
month 6 and during follow-up. 
HBV infections 
Despite passive-active immunization 1% (2/195) of 
infants, one in each group, became HBsAg-positive and 
developed the HBV carrier state. Both infants had 
HBeAg-positive HBsAg carrier mothers with high levels 
of HBV DNA (223 pg ml- ' and 193 pg ml- 1 by Abbott 
HBV DNA assay) and had detectable HBsAg before the 
age of 4 months. The HBsAg carrier ates among infants 
born to HBsAg- and HBeAg-positive mothers were 8% 
(95% CI: 0.19-36.03) and 6% (95% CI: 0.15-28.69) in 
groups E and F, respectively. At 12 months of age, 18% 
of infants (18/98) on schedule E compared with 20% 
of infants (14/70) on schedule F were anti-HBc-positive. 
At the age of 24 months even infants, including the two 
infants who were HBsAg-positive, tested anti-HBc- 
positive. The total number of HBV infections was similar 
for both groups: three (3%) of 102 infants in group E 
(95% CI: 0.62-8.77) and four (4%) of 93 infants in group 
F (95% CI: 1.18 10.65). The inapparent HBV infections 
at 24 months of age (anti-HBc-positive only) were 
observed both in infants born to HBsAg- and 
HBeAg-positive mothers and in infants born to 
HBeAg-negative mothers. 
Vaccination interval 
The median ages at which infants were given 
the first dose of vaccine are given in Table 4. For some 
Table 2 Anti-HBs levels in infants of HBsAg-positive mothers who responded to passive-active immunization according to schedule E or F 
Anti-HBs seroconversion (~>10 IU I 1) Anti-HBs levels (lU 1-1) 
Schedule E Schedule F Schedule E Schedule F 
Month n (%) n (%) p value a GMT (_+2 s.e.m.) GMT (_2 s.e.m.) p value ~ 
3 90/94 (96) 67/73 (92) NS 40 (36-44) 58 (48-71) <<0.001 
4 82/89 (92) 74/75 (99) NS 25 (21-29) 148 (124-176) <<0.001 
6 89/91 (98) 74/76 (97) NS 374 (264-530) 733 (507-1060) 0.02 
11 90/91 (99) 64/65 (98) NS 746 (567-981) 1126 (776-1636) NS 
12 89/90 (99) 68/69 (99) NS 9317 (6556-13 237) 9699 (6476-14 528) NS 
24 85/88 (97) 67/68 (99) NS 1727 (1216-2452) 1125 (767-1649) NS 
NS, not significant 
aFisher's exact test 
~Wilcoxon rank sum test 
Table 3 Anti-HBs levels in infants of HBsAg-positive mothers after administration of plasma vaccine (historic controls) or recombinant hepatitis B 
vaccine (group F) 
Anti-HBs seroconversion Anti-HBs levels (IU 1-1) 
Plasma Recombinant Plasma Recombinant 
Month n (%) n (%) p value a GMT (4-2 s.e.m.) GMT (4-2 s.e.m.) p value b 
3 94/99 (95) 67/73 (92) NS 32 (29-37) 58 (48-71) <<0.001 
6 105/107 (98) 74/76 (97) NS 1120 (812-1545) 733 (507-1060) <<0.001 
11 95/98 (97) 64/65 (98) NS 2360 (1832-3041 ) 1126 (776-1636) << 0.001 
12 95/99 (96) 68/69 (99) NS 15739 (11 738-21 104) 9699 (6475-14528) <<0.001 
24 87/91 (96) 67/68 (99) NS 1728 (1284-2325) 1125 (767-1649) <<0.001 
NS, not significant 
aFisher's exact test 
bWilcoxon rank sum test 
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Table 4 Length of time (days) between birth and the administration of 
the first dose of hepatitis B vaccine to infants on schedule E or F 
First dose of vaccine Schedule E Schedule F p value 
Infants (no.) 102 93 
Target age (days) 91 91 
Median age (days) 96 94 
Mean age (s.d.) 100 (16) 99 (17) 
5th to 95th percentiles 84-125 83-148 
0.12 a 
aWilcoxon-Mann-Whitney test 
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Figure 2 The effect of time on the passively acquired anti-HBs levels 
between birth and the first dose of vaccine (target age 91 days). Anti-HBs 
titres >~1 IU ~ are shown 
infants, the 0 to 3 month interval was extremely long. For 
instance, 21% of infants on schedule E (21/99) and 20% 
of infants (18/90) on schedule F received their injection 
at month 3 more than 2 weeks later than the 
target age (91 days). 
Figure2 illustrates the relationship between the 
time at which the month 3 blood sample was taken 
(target age 91 days) and the level of anti-HBs acquired 
passively at birth. As the 0 to 3 month interval increased, 
the antibody level decreased significantly (p<0.001). 
From Figure 2 it can also be deduced that the passively 
acquired antibodies last approximately 5 months in most 
infants before falling below the critical level of 10 IU 1-1. 
Ten infants, however, had no protective l vels of anti-HBs 
at 3 months of age. Five infants had less than 10 IU 1-1 
anti-HBs and the other five infants had no detectable 
anti-HBs. Only two of these infants, one in each group, 
received their first dose beyond the mean age of vaccine 
administration plus the standard deviation. Except for 
the one infant who became an HBsAg carrier, all infants 
with anti-HBs < 10 IU 1-1 at 3 months of age were born 
to HBeAg-negative mothers and developed a protective 
immune response from month 6 onwards. 
D ISCUSSION 
We examined the need for an additional HBIg dose at 
3 months of age in infants receiving a high dose of HBIg 
at birth and simultaneous injections of hepatitis B vaccine 
and DTP-pol io vaccine at 3, 4, 5 and 11 months of age. 
The rates of seroprotection (anti-HBs t> t0 IU 1-1) in 
group E, without he additional dose of HBIg, and group 
F were similar in all cases. No significant benefit from 
the additional HBIg dose at 3 months was observed, 
especially during the first 6 months of life when the effect 
of HBIg given at birth is waning 7. 
More importantly, we found no differences in the 
number of infants who became HBsAg-positive in group 
E (8%) and group F (6%), whereas the number of infants 
born to HBsAg- and HBeAg-positive mothers was similar 
in both groups (Table 1). Although the 95% CI for the 
difference between the two population proportions range 
from -16% to 20%, showing the relative imprecision 
due to the limited sample size, these percentages are 
comparable to the number of HBsAg-positive infections 
(8%; 95% CI: 1.7 21.9) observed in the larger group of 
historic controls who received two doses of HBIg at 0 
and 3 months and the plasma-derived vaccine at 3, 4, 5 
and 11 months of age 3. The percentage of infants on 
schedule E or F with inapparent HBV infection 
(anti-HBc-positive only) was also similar for both groups. 
After a high dose of HBIg given at birth, antibodies tend 
to remain above the critical level of 10 IU 1-1 anti-HBs 
for approximately 5 months (Figure 2). 
The immune response provided by vaccination 
initiated at 3 months of age is rapid and strong 2"8 1o 
resulting in similar protective efficacy (98% versus 
90 93%) compared with vaccination starting at birth 2's. 
Our study results of excellent protective fficacy after 
delayed active immunization support the findings by 
Beasley et al. s. 
Ten infants had no protective levels of anti-HBs at 3 
months of age. All infants but one were born to 
HBeAg-negative mothers and the reasons for the absence 
of anti-HBs levels >~IOIUI -~ are not clear. The low 
levels of anti-HBs in these infants may have been caused 
either by failures in the administration of HBIg or by 
consumption of the passively administered anti-HBs 
antibodies. For programmes with delayed active 
immunization, monitoring of HBIg administration is 
indicated. In addition, we advocate the use of l ml of 
HBIg instead of the usually recommended ose of 
0.5 ml. 
The practical consequences of our findings are that a 
schedule with high efficacy and compliance at relatively 
low cost can be implemented in the Dutch childcare 
system to prevent perinatal infections in infants of 
HBsAg-positive mothers, provided that administration 
of hepatitis B vaccine in clinical practice is timely. 
The data from this study further demonstrate hat the 
recombinant hepatitis B vaccine is efficacious in inducing 
high antibody levels in infants of HBsAg-positive 
mothers. Although we, like others 5, found that the 
recombinant vaccine and plasma vaccine are equally 
immunogenic n inducing levels of anti-HBs >~ 10 IU 1 1 
the GMTs of anti-HBs antibodies in infants given the 
recombinant vaccine were significantly lower than those 
observed with plasma vaccine. Others have also 
demonstrated that the recombinant vaccine (10#g or 
20/~g Engerix-B) produces a relatively lower antibody 
titre than the plasma vaccine (10#g or 20/~g HBvax, 
MSD) 11'~2. Differences in GMTs between the current 
recombinant vaccine study and our previous tudy using 
the plasma vaccine require careful interpretation. Even 
though the vaccination regime and methods of testing 
(radioimmunoassay, Ausab, Abbott) were similar, the 
vaccine doses were different and the study populations 
might have changed over time. It should also be noted 
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that antibodies were assayed with kits containing 
plasma-derived HBsAg as the antigen. Conceivably, 
antibodies induced by recombinant-derived HBsAg may 
be only partially homologous to the plasma-derived 
HBsAg x3. The higher geometric mean titres in group F 
during the first 6 months are probably the result of the 
passively acquired antibodies, ince simultaneous admini- 
stration of HBIg and vaccine was not found to either 
reduce or stimulate the immune response 14. 
The possibility of giving reduced oses of vaccine to 
lower the cost has been evaluated by Lee et al. 15. 
As the protective fficacy decreased with the dose of 
antigen given, the authors recommended that lower doses 
of vaccine should not be used for infants of carrier 
mothers. Since a rapid and strong immune response to 
the vaccine may enhance optimal early protection and 
long-lasting immunity, we support he recommendation 
of the Dutch Health Authorities to use the adult dose of 
the recombinant vaccine. 
The recommendations on HBIg and hepatitis B 
vaccine apply only for developed countries where 
maternal screening for HBsAg and passive-active 
immunization i  infants of HBsAg-positive women is the 
standard policy for the prevention of perinatal hepatitis 
B infection. In the Netherlands, where many home 
deliveries take place, HBIg should be given at birth by 
the person assisting in the delivery. The dose should be 
adequate o maintain protection until the age of 3 months 
when hepatitis B vaccination i  infants is started at the 
same time as DTP-polio vaccination at the Child Health 
Clinics. 
ACKNOWLEDGEMENTS 
This study is generously funded by a grant from the 
Praeventiefonds, The Netherlands (no. 28-760-2). The 
authors thank J. Boot and W.C.J. Hop for their technical 
assistance and statistical advice, and the members of the 
Virology Department, Erasmus University, Rotterdam, 
The Netherlands for their support. 
REFERENCES 
1 Mazel, J.A., Schalm, S.W., de Gast, G.C., Nuijten, A.S.M., 
Heijtink, R.A., Botman, M.J. et al. Passive-active immunization in 
Hepatitis B vaccination of neonates: P.M. Grosheide et al, 
neonates of HBsAg-positive carrier mothers: preliminary observ- 
ations. BMJ 1984, 288, 513-515 
2 Schalm, S.W., Mazel, J,A., de Gast, G.C., Heijtink, R.A., Botman, M.J., 
B~nffer, J.R.J. et al. Prevention of hepatitis B injection in newborns 
through mass screening and delayed vaccination of all infants of 
mothers with hepatitis B surface antigen. Pediatrics 1989, 83, 
1041-1048 
3 Grosheide, P.M., del Canho, R., Heijtink, R.A., Nuijten, A.S.M., 
Zwijnenberg, J., B&nffer, J.R.J. et al. Passive-active immunization 
in infants of hepatitis B e antigen-positive mothers: comparison of 
the efficacy of early and delayed active immunization. Am. J. Dis. 
Child. 1993, 147, 1316-1320 
4 Beasley, R.P., Hwang, L.Y., Stevens, C.E., Lin, C.C., Hsieh, F.J., 
Wang, K.Y. et al. Efficacy of hepatitis B immune globulin for 
prevention of perinatal transmission of the hepatitis B virus carrier 
state: final report of a randomized double-blind placebo-controlled 
trial. Hepatology 1983, 3, 136-141 
5 Cadranel, S., Zeghlache, S., Fernandez, S., Safary, A. and 
Andre, F.E. Vaccination of newborns of HBsAg positive carrier 
mothers with a recombinant DNA hepatitis B vaccine. Postgrad. 
Med. J. 1987, 63 (Suppl 2), 159-160 
6 Lenter, C. (Ed). Geigy Scientific Tables 8th edn, Geigy, Basel, 
Switzerland, 1982, pp. 89-102 
7 Beasley, R.P. and Hwang, L.L. Postnatal infectivity of hepatitis B 
surface antigen-carrier mothers. J. Infect, Dis. 1983, 147, 185-190 
8 Beasley, R.P., Hwang, L.-Y., Lee, G.C.-H., Lan, C.-C., Roan, C.-H., 
Huang, F.-Y. and Chen, C.-L. Prevention of perinatally transmitted 
hepatitis B virus infections with hepatitis B immune globulin and 
hepatitis B vaccine. Lancet 1983, ii, 1099-1102 
9 Piazza, M., Picciotto, L., Villari, R., Guadagnino, V., Orlando, R., 
Isabella, L. et al. Hepatitis B immunization with a reduced number 
of doses in newborn babies and children. Lancet 1985, |, 949-951 
10 Piazza, M., Picciotto, L., Villari, R., Guadagnino, V., Orlando, R., 
Macchia, V. et al. Two-dose hepatitis B immunisation regimen for 
infants. Lancet 1985, ii, 1120-1121 
11 Panda, S.K., Ramesh, R., Rao, K.V.S., Gupta, A., Zuckerman, A.J. 
and Nayak, N.C. Comparative valuation of the immunogenicity of 
yeast-derived (recombinant) and plasma-derived hepatitis B vaccine 
in infants. J. Med. Virol. 1991, 35, 297-302 
12 Payton, C.D., Scarisbrick, D.A., Sikotra, S. and Flower, A.J.E. 
Vaccination against hepatitis B: comparison of intradermal and 
intramuscular administration of plasma derived and recombinant 
vaccines. Epidemiol. Infect. 1993, 110, 177-180 
13 McCartney, R.A., Harbour, J., Roome, A.P.C.H. and Caul, E.O. 
Comparison of enhanced chemiluminescence and microparticle 
enzyme immunoassay for the measurement of hepatitis B surface 
antibody. Vaccine 1993, 11,941-945 
14 Lelie, P.N., Reesink, H.W., Grijm, R., de Jong-van Manen, S.Th. and 
Reerink-Brongers, E.E. Simultaneous passive and active immuniz- 
ation against hepatitis B; non-interference of hepatitis B immune 
globulin with the anti-HBs response to reduced doses of 
heat-inactivated hepatitis B vaccine. Hepatology 1986, 8, 971-975 
15 Lee, C.Y., Hwang, L.Y. and Beasley, R.P. Low-dose hepatitis B 
vaccine. Lancet 1989, ii, 860-861 
Vaccine 1994 Vo lume 12 Number  12 1063 
